Testosterone undecanoate (TU) - NebidoTM
Phase 3Completed 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Hypogonadism
Conditions
Hypogonadism
Trial Timeline
Feb 1, 2003 โ Oct 1, 2007
NCT ID
NCT00220298About Testosterone undecanoate (TU) - NebidoTM
Testosterone undecanoate (TU) - NebidoTM is a phase 3 stage product being developed by Bayer for Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT00220298. Target conditions include Hypogonadism.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00220298 | Phase 3 | Completed |
Competing Products
20 competing products in Hypogonadism